302722c6-102e-4b1b-845e-78920380e337
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.280
- MITOTIC_SPINDLE+0.220
- TGF_BETA_SIGNALING+0.120
- HEDGEHOG_SIGNALING+0.110
- NOTCH_SIGNALING+0.090
- KRAS_SIGNALING_DN+0.080
- ESTROGEN_RESPONSE_EARLY+0.070
- MYC_TARGETS_V2+0.000
- APICAL_JUNCTION-0.030
- PEROXISOME-0.040
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.470
- ALLOGRAFT_REJECTION-0.460
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- CHOLESTEROL_HOMEOSTASIS-0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- COMPLEMENT-0.390
- INFLAMMATORY_RESPONSE-0.390
- FATTY_ACID_METABOLISM-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- MTORC1_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d333233b-e431-462b-ae35-c3b4c6ab3a40 | — | — | 0.918 |
| 2 | MBCProject_0719_T1_RNA | — | A | 0.917 |
| 3 | s0102877 | — | — | 0.917 |
| 4 | BS_Q13FQ8FV | Diffuse intrinsic pontine glioma | — | 0.896 |
| 5 | TCGA-A7-A0DC-01B-04R-A22O-07 | — | D | 0.889 |
| 6 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.888 |
| 7 | SRR8613811 | — | D | 0.885 |
| 8 | MDT-AP-0222 | Med | Medulloblastoma | 0.884 |
| 9 | MDT-AP-0130 | Med | Medulloblastoma | 0.883 |
| 10 | TCGA-OR-A5L8-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.879 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 7 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |